- Home
- TRIP vs ALVO Comparison
TRIP vs ALVO Comparison
Compare TRIP & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | ALVO |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRIP | ALVO |
|---|---|---|
| Price | $11.91 | $3.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $14.40 | $8.00 |
| AVG Volume (30 Days) | ★ 3.8M | 507.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,556,000,000.00 | N/A |
| Revenue This Year | $3.33 | $13.28 |
| Revenue Next Year | $5.12 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.01 | $2.94 |
| 52 Week High | $20.16 | $10.79 |
Technical Indicators
Market Signals| Indicator | TRIP | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 64.68 | 40.74 |
| Support Level | $9.28 | N/A |
| Resistance Level | $15.37 | $3.74 |
| Average True Range (ATR) | 0.52 | 0.15 |
| MACD | 0.27 | -0.03 |
| Stochastic Oscillator | 83.60 | 24.00 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025, and TheFork, its dining brand, represented 12% of sales.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.